PRINCETON, N.J.—Peter J. Mariani, the Chief Financial Officer of Cytosorbents Corp (NASDAQ:), recently acquired a substantial amount of the company’s common stock. According to a recent SEC filing, Mariani purchased 20,000 shares on December 13, 2024, at an average price of $0.9647 per share. This transaction amounted to a total value of $19,294. The purchase comes as the stock shows strong momentum, with InvestingPro data showing a 14.75% gain over the past week. The company, currently valued at approximately $55 million, has caught analysts’ attention with price targets ranging from $1 to $10 per share.
The shares were bought in open market transactions at varying prices ranging from $0.8902 to $1.09. Following this purchase, Mariani now directly owns 401,363 shares of Cytosorbents, which includes restricted stock units (RSUs) that are subject to vesting conditions. According to InvestingPro, the company’s current price represents a significant discount to its Fair Value, suggesting potential upside opportunity. Subscribers can access additional insights, including 6 more ProTips and a comprehensive Pro Research Report, which provides deep-dive analysis of CTSO’s financial health and growth prospects.
In other recent news, CytoSorbents Corporation has announced the terms of an upcoming Rights Offering, aiming to raise between $3.0 million and $5.0 million. This move could potentially double the liquidity for the company, which is crucial given the recent analysis indicating a negative free cash flow of $18.8 million in the last twelve months. The proceeds are intended for general corporate purposes and to support operations through key regulatory decisions expected in 2025.
In terms of earnings and revenue, the company reported an 11% year-over-year increase in product sales in the third quarter of 2024, reaching $8.6 million. CytoSorbents’ flagship product, CytoSorb, has generated nearly $34 million in sales over the past year.
Recently, the company has made progress in its blood purification technology, particularly in critical care and cardiac surgery applications. CytoSorbents is also preparing for the launch of DrugSorb ATR, a device aimed at reducing perioperative bleeding, which has earned two FDA breakthrough device designations. The company has managed to decrease its operating expenses by 25% and reduced its cash burn to $2.7 million. Decisions from the FDA and Health Canada on DrugSorb ATR are expected to be made in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
